Antibodies against botulinum neurotoxin type A as a cause of treatment failure after the first detrusor injection.
Botulinum neurotoxins are increasingly used in treatment for hyperactive detrusor and sphincter function. Although reported results are promising, conditions in some patients are refractory. We report what we believe to be the first urologic case of therapy failure possibly induced by botulinum toxin antibodies after just one injection and discuss treatment alternatives based on experience in other fields.
Schulte-Baukloh
Heinrich
H
Department of Urology, St. Hedwig Hospital, Charité Medical School, Humboldt University, Berlin, Germany. hschultebaukloh@hotmail.com
Bigalke
Hans
H
Heine
Gert
G
Pape
Daniela
D
Stuerzebecher
Burkard
B
Miller
Kurt
K
Knispel
Helmut H
HH
D000283:Administration, Intravesical; D000368:Aged; D000906:Antibodies / Q000032:analysis; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D008297:Male; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000276:immunology*; D009498:Neurotoxins / Q000008:administration & dosage / Q000276:immunology*; D017211:Treatment Failure; D014555:Urination Disorders / Q000188:drug therapy* / Q000503:physiopathology; D014563:Urodynamics
D000906:Antibodies; D009465:Neuromuscular Agents; D009498:Neurotoxins; D019274:Botulinum Toxins, Type A